dc.contributor.author |
Bueno, Clara |
dc.contributor.author |
Velasco-Hernández, Talia |
dc.contributor.author |
Gutiérrez-Agüera, Francisco |
dc.contributor.author |
Zanetti, S. R. |
dc.contributor.author |
Baroni, Matteo Libero. |
dc.contributor.author |
Sánchez-Martínez, D. |
dc.contributor.author |
Molina, Oscar |
dc.contributor.author |
Closa, A. |
dc.contributor.author |
Agraz-Doblás, Antonio |
dc.contributor.author |
Marín, P. |
dc.contributor.author |
Eyras, E. |
dc.contributor.author |
Varela, Ignacio |
dc.contributor.author |
Menéndez Bujan, Pablo |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2019 |
dc.identifier |
https://ddd.uab.cat/record/236892 |
dc.identifier |
urn:10.1038/s41375-019-0418-8 |
dc.identifier |
urn:oai:ddd.uab.cat:236892 |
dc.identifier |
urn:scopus_id:85061691718 |
dc.identifier |
urn:articleid:14765551v33n8p2090 |
dc.identifier |
urn:pmid:30778134 |
dc.identifier |
urn:pmc-uid:6756031 |
dc.identifier |
urn:pmcid:PMC6756031 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:6756031 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
European Commission 646903 |
dc.relation |
European Commission 811220 |
dc.relation |
Ministerio de Economía y Competitividad SAF-SAF2016-80481-R |
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca SGR330 |
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca SGR102 |
dc.relation |
Instituto de Salud Carlos III PI14-01191 |
dc.relation |
Leukemia ; Vol. 33 Núm. 8 (january 2019), p. 2090-2125 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Immunotherapy |
dc.subject |
Acute lymphocytic leukaemia |
dc.title |
CD133-directed CAR T-cells for MLL leukemia : on-target, off-tumor myeloablative toxicity |
dc.type |
Article |
dc.description.abstract |
Altres ajuts: This work has been supported by the the Spanish Association against cancer (AECC-CI-2015) to CB. PM also acknowledges financial support from the Obra Social La Caixa-Fundaciò Josep Carreras. SRZ and TV are supported by a Marie Curie fellowships. OM is supported by the Catalan Government through a Beatriu de Pinos fellowship. |